These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 8989922)

  • 41. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
    Xu H; Cheepala S; McCauley E; Coombes K; Xiao L; Fischer SM; Clifford JL
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):969-79. PubMed ID: 16467112
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of vitamin E on tamoxifen-treated breast cancer cells.
    Peralta EA; Viegas ML; Louis S; Engle DL; Dunnington GL
    Surgery; 2006 Oct; 140(4):607-14; discussion 614-5. PubMed ID: 17011908
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The synergistic inhibitory effect of 5-aza-2-deoxycytidine and Tamoxifen on estrogen receptor alpha negative breast cancer cell lines in vitro].
    Tang B; Peng ZH; Jiang J
    Zhonghua Wai Ke Za Zhi; 2005 Dec; 43(23):1545-9. PubMed ID: 16412295
    [TBL] [Abstract][Full Text] [Related]  

  • 44. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid.
    Delia D; Aiello A; Lombardi L; Pelicci PG; Grignani F; Grignani F; Formelli F; Menard S; Costa A; Veronesi U
    Cancer Res; 1993 Dec; 53(24):6036-41. PubMed ID: 8261419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 4-HPR Is an Endoplasmic Reticulum Stress Aggravator and Sensitizes Breast Cancer Cells Resistant to TRAIL/Apo2L.
    Anding AL; Jones JD; Newton MA; Curley RW; Clagett-Dame M
    Anticancer Res; 2018 Aug; 38(8):4403-4416. PubMed ID: 30061204
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined effect of chemopreventive agent N-(4-hydroxyphenyl) retinamide (4-HPR) and gamma-radiation on bladder cancer cell lines.
    Zou C; Wang L; Liebert M; Grossman HB; Lotan R; Wei Q
    Int J Oncol; 1998 Nov; 13(5):1037-41. PubMed ID: 9772297
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer.
    Conley B; O'Shaughnessy J; Prindiville S; Lawrence J; Chow C; Jones E; Merino MJ; Kaiser-Kupfer MI; Caruso RC; Podgor M; Goldspiel B; Venzon D; Danforth D; Wu S; Noone M; Goldstein J; Cowan KH; Zujewski J
    J Clin Oncol; 2000 Jan; 18(2):275-83. PubMed ID: 10637240
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination of 5-deoxy-5-fluorouridine and tamoxifen show cell-type specific antagonistic and cooperative effects on cytotoxicity in human mammary carcinoma cells.
    Bollig A; Du QQ; Fan ST; Yu B; Sarkar FH; Liao J
    Oncol Rep; 2005 Jul; 14(1):177-83. PubMed ID: 15944786
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Associations of retinoids, tamoxifen and alpha-interferon 2a in human breast cancer.
    Toma S; Raffo P; Isnardi L; Riccardi L; Defrancisci E; Maselli G; Dastoli G; Palumbo R
    Int J Oncol; 1997 Mar; 10(3):597-607. PubMed ID: 21533419
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
    Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
    Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer.
    Porzsolt F; Otto AM; Trauschel B; Buck C; Wawer AW; Schönenberger H
    J Cancer Res Clin Oncol; 1989; 115(5):465-9. PubMed ID: 2478560
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines.
    Kalemkerian GP; Slusher R; Ramalingam S; Gadgeel S; Mabry M
    J Natl Cancer Inst; 1995 Nov; 87(22):1674-80. PubMed ID: 7473815
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tamoxifen synergizes with 4-(E)-{(4-hydroxyphenylimino)-methylbenzene, 1,2-diol} and 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, novel azaresveratrol analogs, in inhibiting the proliferation of breast cancer cells.
    Ronghe A; Chatterjee A; Bhat NK; Padhye S; Bhat HK
    Oncotarget; 2016 Aug; 7(32):51747-51762. PubMed ID: 27351134
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide.
    Pellegrini R; Mariotti A; Tagliabue E; Bressan R; Bunone G; Coradini D; Della Valle G; Formelli F; Cleris L; Radice P
    Cell Growth Differ; 1995 Jul; 6(7):863-9. PubMed ID: 7547508
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of OK-432 (picibanil) on the estrogen receptors of MCF-7 cells and potentiation of antiproliferative effects of tamoxifen in combination with OK-432.
    Aoyagi H; Iino Y; Takeo T; Horii Y; Morishita Y; Horiuchi R
    Oncology; 1997; 54(5):414-23. PubMed ID: 9260604
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cyclosporin A enhances the apoptotic effects of N-(4-hydroxyphenyl)retinamide in breast cancer cells.
    Lim SJ; Simeone AM; Kim CK; Tari AM
    Int J Cancer; 2002 Sep; 101(3):243-7. PubMed ID: 12209974
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells.
    Kang Y; Cortina R; Perry RR
    J Natl Cancer Inst; 1996 Mar; 88(5):279-84. PubMed ID: 8614006
    [TBL] [Abstract][Full Text] [Related]  

  • 59. N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes.
    O'Donnell PH; Guo WX; Reynolds CP; Maurer BJ
    Leukemia; 2002 May; 16(5):902-10. PubMed ID: 11986953
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.
    Reddel RR; Murphy LC; Hall RE; Sutherland RL
    Cancer Res; 1985 Apr; 45(4):1525-31. PubMed ID: 3978620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.